These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35703302)

  • 1. Changing Incidence of Invasive Pneumococcal Disease in Infants Less Than 90 Days of Age Before and After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Blantyre, Malawi: A 14-Year Hospital Based Surveillance Study.
    Koenraads M; Swarthout TD; Bar-Zeev N; Brown C; Msefula J; Denis B; Dube Q; Gordon SB; Heyderman RS; Gladstone MJ; French N
    Pediatr Infect Dis J; 2022 Sep; 41(9):764-768. PubMed ID: 35703302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies.
    Bar-Zeev N; Swarthout TD; Everett DB; Alaerts M; Msefula J; Brown C; Bilima S; Mallewa J; King C; von Gottberg A; Verani JR; Whitney CG; Mwansambo C; Gordon SB; Cunliffe NA; French N; Heyderman RS;
    Lancet Glob Health; 2021 Jul; 9(7):e989-e998. PubMed ID: 34143997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasiveness potential of pneumococcal serotypes in children after introduction of PCV13 in Blantyre, Malawi.
    Kirolos A; Swarthout TD; Mataya AA; Bonomali F; Brown C; Msefula J; Bar-Zeev N; Iroh Tam PY; Alaerts M; Bilima S; Heyderman RS; French N
    BMC Infect Dis; 2023 Jan; 23(1):56. PubMed ID: 36703117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive Pneumococcal Disease in UK Children <1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now?
    Kent A; Makwana A; Sheppard CL; Collins S; Fry NK; Heath PT; Ramsay M; Ladhani SN
    Clin Infect Dis; 2019 Jun; 69(1):84-90. PubMed ID: 30281069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
    Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study.
    Swarthout TD; Henrion MYR; Thindwa D; Meiring JE; Mbewe M; Kalizang'Oma A; Brown C; Msefula J; Moyo B; Mataya AA; Barnaba S; Pearce E; Gordon M; Goldblatt D; French N; Heyderman RS
    Lancet Infect Dis; 2022 Dec; 22(12):1737-1747. PubMed ID: 36029796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use.
    Baxter R; Aukes L; Pelton SI; Yee A; Klein NP; Gruber WC; Scott DA; Center KJ
    J Pediatric Infect Dis Soc; 2021 Mar; 10(2):141-150. PubMed ID: 32415771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
    Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
    Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease.
    Gaviria-Agudelo CL; Jordan-Villegas A; Garcia C; McCracken GH
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):253-259. PubMed ID: 26907814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.
    Ben-Shimol S; Regev-Yochay G; Givon-Lavi N; van der Beek BA; Brosh-Nissimov T; Peretz A; Megged O; Dagan R; ;
    Clin Infect Dis; 2022 May; 74(9):1639-1649. PubMed ID: 34293091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing Trends of Invasive Pneumococcal Disease in the Era of Conjugate Pneumococcal Vaccination in Olmsted County: A Population-Based Study.
    Chesdachai S; Graden AR; DeSimone DC; Weaver AL; Baddour LM; Joshi AY
    Mayo Clin Proc; 2022 Dec; 97(12):2304-2313. PubMed ID: 36344297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
    Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.